Moderna shares rose 5.3% after the company raised its 2026 revenue growth framework to 15%–25%, from up to 10%, citing stronger-than-expected U.S. and international revenue in Q3 and visibility into Q4. The quarter also showed a return to profitability, though some of the sales strength reflected shipment timing and cost of sales rose faster than revenue.
Moderna's shares dropped 5.4% following Q2 as investors reacted negatively to cautious revenue guidance coupled with ongoing net losses, despite some margin improvements and pipeline progress.
Moderna’s shares rose 3.0% following a quarter marked by solid international revenue growth and significant cost reductions, offsetting the expected impact from a large litigation settlement charge.
Moderna reported third-quarter 2025 revenues of $1 billion, highlighting a significant ongoing focus on cost reductions despite a net loss of $200 million, driven by lower COVID vaccine demand.